Trials Sponsors Conditions Drugs Pricing

Conditions

Psoriasis

Keywords

Psoriasis

Outcome Measures

Primary Outcomes (4)

Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 24
Week 24
The proportion of subjects who achieve a PGA score of 0 or 1 at Week 24
Week 24
Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 52
Week 52
The proportion of subjects who achieve a PGA score of 0 or 1 at Week 52
Week 52

Secondary Outcomes (4)

Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 24
Week 24
Changes from Baseline in the DLQI total score at Week 24
Week 24
Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 52
Week 52
Changes from Baseline in the DLQI total score at Week 52
Week 52

Study Arms (2)

A

EXPERIMENTAL

ABT-874

Drug: ABT-874

B

ACTIVE COMPARATOR

Methotrexate

Drug: Methotrexate

Interventions

ABT-874Drug

200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection

MethotrexateDrug

5.0 to 25 mg weekly

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI 12 or above, PGA 3 or above

You may not qualify if:

Sponsors & Collaborators

AbbVie (prior sponsor, Abbott)
Industrylead

Study Sites (43)

Site Reference ID/Investigator# 9904

Graz, 8036, Austria

Site Reference ID/Investigator# 11001

Vienna, 1090, Austria

Site Reference ID/Investigator# 12763

Vienna, A-1030, Austria

Site Reference ID/Investigator# 8022

Brussels, 1200, Belgium

Site Reference ID/Investigator# 13104

Barrie, L4M 6L2, Canada

Site Reference ID/Investigator# 13161

Halifax, B3H 0A2, Canada

Site Reference ID/Investigator# 11864

Hamilton, L8N 1V6, Canada

Related Publications (2)

Inzinger M, Weger W, Salmhofer W, Wolf P. Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab. Acta Derm Venereol. 2012 Jul;92(4):357-8. doi: 10.2340/00015555-1243. No abstract available.
PMID: 22169986DERIVED
Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586-96. doi: 10.1056/NEJMoa1010858.
PMID: 22029980DERIVED

MeSH Terms

Conditions

Psoriasis

Interventions

briakinumabMethotrexate

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

AminopterinPterinsPteridinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

Martin Kaul, MD
AbbVie
STUDY CHAIR

Enrollment

317 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 15, 2008

First Posted

May 19, 2008

Study Start

April 2008

Date type not reported

This date has not been verified as actual or estimated.

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (4)

Study Arms (2)

A

B

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (43)

Related Publications (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (4)

Study Arms (2)

A

B

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (43)

Related Publications (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations